Eli Lilly (NYE: LLY) has announced that results from the SURPASS-2 study have been published in The New England Journal of Medicine, showing that its investigational drug tirzepatide achieved superior HbA1C and weight reductions compared to semaglutide in people with type 2 diabetes.
Weight management support in type 2 diabetes is important as approximately 85% of people with type 2 are carrying extra weight or are living with obesity, with figures likely to have increased during COVID lockdowns, the US pharma major noted.
A prespecified exploratory composite endpoint comprised of participants who achieved an HbA1C level less than or equal to 6.5% and weight loss of 10% or greater, while not experiencing hypoglycemia less than 54mg/dL (3 mmol/L) or severe hypoglycemia, was evaluated. Across the three doses of tirzepatide, 32% (5mg), 51% (10mg) and 60% (15mg) of participants achieved this composite endpoint compared to 22% of participants taking semaglutide 1mg.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze